EMA's Guido Rasi Receives Leadership Award
EMA's Executive Director, Guido Rasi received the 2014 European Rare Disease Leadership Award 2014.
The European Medicines Agency's Executive Director, Guido Rasi, together with Paola Testori Coggi from the European Commission and Luca Pani from AIFA, have received the 2014 European Rare Disease Leadership Award 2014.
The award has been given by EURORDIS, a non-governmental patient-driven alliance of patient organizations representing 614 rare disease patient groups in 58 countries.
Today, 28 February 2014, is Rare Disease Day, and EURORDIS is planning a series of activities and events, including a television interview in Kenya, a Fun Play Day in Lebanon, an informational awareness-raising campaign in Paraguay, a march in Austria, an auction in Canada, a photo exhibit in China, and a seminar in India. It says thousands of participants from over 80 countries will be involved in the event.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
